AnaptysBio (ANAB) Business Model Shift, Earnings & Stock Surge

Font: Financial Modeling Prep  • May 01, 2026

AnaptysBio (NASDAQ: ANAB) Transforms Business Model Amidst Earnings Expectations and Stock Volatility

AnaptysBio, Inc. (NASDAQ:ANAB) has transitioned its business model to focus on royalty management after spinning off its biopharma operations.
Upcoming quarterly earnings forecasts predict a loss, with some analysts anticipating a significant year-over-year improvement in EPS.
A favorable court ruling protecting Jemperli royalty rates led to a 14.8% stock price increase, highlighting the impact of legal decisions on ANAB's financial outlook.

AnaptysBio, Inc. (NASDAQ:ANAB) recently changed its business model. As highlighted by GlobeNewswire, the company completed the spin-off of its biopharma operations, First Tracks Biotherapeutics. ANAB now operates as a royalty management company. Its new focus is managing financial collaborations for its out-licensed assets, Jemperli with GSK (NYSE: GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).

The company is scheduled to release its next quarterly earnings report on May 4th, 2026. Wall Street analysts expect an earnings per share (EPS) of -$0.72 on revenues of approximately $19.98 million. EPS is a company's profit divided by its number of common shares, showing how much money it makes for each share.

A report from Zacks Investment Research provides a slightly different view. It suggests ANAB may report a quarterly loss of $0.77 per share on revenues of around $27.50 million. While still a loss, this would represent a nearly 40% improvement from the same quarter last year, showing a positive trend in earnings despite lower revenues.

Recently, ANAB's stock price increased by 14.8% in a single session to close at $58.88. A key reason for this jump was a favorable court ruling, as highlighted by Zacks Investment Research. The court dismissed a contract claim from a GSK subsidiary, which protects ANAB's current royalty rates for its drug Jemperli.

Looking at its financial health, ANAB has a negative trailing Price-to-Earnings (P/E) ratio of -139.90, which means the company was not profitable over the last twelve months. However, its current ratio is a strong 9.07. This ratio compares assets to liabilities, suggesting ANAB has a solid ability to cover its short-term financial obligations.